Crossmark

Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network

Crossref DOI link: https://doi.org/10.1007/s00277-018-3424-4

Published Online: 2018-07-15

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zappasodi, Patrizia

Marbello, Laura

Borlenghi, Erika

Fumagalli, Monica

Bernardi, Massimo

Fracchiolla, Nicola

Mancini, Valentina

Da Vià, Matteo

Ravano, Emanuele

Cerqui, Elisa

Ferretti, Virginia Valeria

Rocca, Barbara

Calvello, Celeste

Cazzola, Mario

Castagnola, Carlo

Rossi, Giuseppe
License Information

Text and Data Mining valid from 2018-07-15
More Information

Article History

Received: 6 March 2018

Accepted: 27 June 2018

First Online: 15 July 2018

Compliance with ethical standards

: The study was approved by the ethical committees of all participating institutions.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below